{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:30:37Z","timestamp":1773894637796,"version":"3.50.1"},"reference-count":120,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T00:00:00Z","timestamp":1590105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The incidence of cutaneous melanoma, a highly malignant skin cancer, is increasing yearly. While surgical removal of the tumor is the mainstay of treatment for patients with locally confined disease, those with metastases face uncertainty when it comes to their treatment. As melanoma is a relatively immunogenic cancer, current guidelines suggest using immunotherapies that can rewire the host immune response to target melanoma tumor cells. Intralesional therapy, where immunomodulatory agents are injected directly into the tumor, are an emerging aspect of treatment for in-transit melanoma because of their ability to mitigate severe off-target immune-related adverse events. However, their immunomodulatory mechanisms are poorly understood. In this review, we will summarize and discuss the different intralesional therapies for metastatic melanoma with respect to their clinical outcomes and immune molecular mechanisms.<\/jats:p>","DOI":"10.3390\/cancers12051321","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T10:18:18Z","timestamp":1590142698000},"page":"1321","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-3331","authenticated-orcid":false,"given":"Dejan","family":"Vidovic","sequence":"first","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carman","family":"Giacomantonio","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,22]]},"reference":[{"key":"ref_1","first-page":"591","article-title":"Vital Signs: Melanoma Incidence and Mortality Trends and Projections\u2014United States, 1982\u20132030","volume":"64","author":"Guy","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_2","unstructured":"(2019, November 26). Melanoma Skin Cancer Statistics\u2014Canadian Cancer Society. Available online: http:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/skin-melanoma\/statistics\/?region=on."},{"key":"ref_3","unstructured":"(2019, November 26). Survival Statistics for Melanoma Skin Cancer\u2014Canadian Cancer Society. Available online: http:\/\/www.cancer.ca\/en\/cancer-information\/cancer-type\/skin-melanoma\/prognosis-and-survival\/survival-statistics\/?region=on."},{"key":"ref_4","first-page":"120","article-title":"Epidemiology of skin cancer","volume":"810","author":"Leiter","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ward, W.H., and Farma, J.M. (2017). Epidemiology of Melanoma. Cutaneous Melanoma: Etiology and Therapy, Codon Publications.","DOI":"10.15586\/codon.cutaneousmelanoma.2017"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/CEJ.0000000000000056","article-title":"Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: A systematic review","volume":"24","author":"Gordon","year":"2015","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_7","first-page":"229","article-title":"Cost of Cutaneous Melanoma by Tumor Stage: A Descriptive Analysis","volume":"108","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"ref_8","first-page":"450","article-title":"Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw","volume":"14","author":"Coit","year":"2016","journal-title":"JNCCN"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA. Cancer J. Clin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/dth.12276","article-title":"Malignant melanoma in organ transplant recipients: Incidence, outcomes, and management strategies: A review of literature","volume":"29","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three 3component phases\u2014Elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"106132","DOI":"10.18632\/oncotarget.22190","article-title":"Immune system and melanoma biology: A balance between immunosurveillance and immune escape","volume":"8","author":"Passarelli","year":"2017","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1126\/science.1063916","article-title":"Regulation of cutaneous malignancy by gammadelta T cells","volume":"294","author":"Girardi","year":"2001","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","article-title":"Biology and regulation of IL-2: From molecular mechanisms to human therapy","volume":"18","author":"Spolski","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fimmu.2012.00161","article-title":"Ricciardi-Castagnoli, P. Interleukin-2 Production by Dendritic Cells and its Immuno-Regulatory Functions","volume":"3","author":"Zelante","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1002\/cncr.25156","article-title":"High response rate after intratumoral treatment with interleukin-2","volume":"116","author":"Weide","year":"2010","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/jso.23702","article-title":"Treatment of in-transit melanoma with intra-lesional interleukin-2: A systematic review","volume":"110","author":"Byers","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1245\/s10434-014-4199-z","article-title":"Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease","volume":"22","author":"Hassan","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jso.21968","article-title":"Intra-lesional interleukin-2 for the treatment of in-transit melanoma","volume":"104","author":"Boyd","year":"2011","journal-title":"J. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0001-7310(09)71905-2","article-title":"Experiencia en el tratamiento de satelitosis y met\u00e1stasis cut\u00e1neas en tr\u00e1nsito de melanoma con interleucina 2 intralesional","volume":"100","author":"Dehesa","year":"2009","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e12612","DOI":"10.1111\/dth.12612","article-title":"Successful treatment of cutaneous metastatic melanoma with high-dose intralesional interleukin-2 treatment combined with cryosurgery","volume":"31","year":"2018","journal-title":"Dermatol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00262-017-2012-0","article-title":"Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab","volume":"66","author":"Heppt","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/healthcare1010096","article-title":"Scalp In-Transit Metastatic Melanoma Treated with Interleukin-2 and Pulsed Dye Laser","volume":"1","author":"Wang","year":"2013","journal-title":"Healthcare"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fonc.2017.00061","article-title":"Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette\u2013Gu\u00e9rin","volume":"7","author":"Yang","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF01789050","article-title":"Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Gu\u00e9rin therapy for locally metastatic melanoma","volume":"32","author":"Cohen","year":"1991","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fimmu.2017.00965","article-title":"Mycobacterium bovis Bacillus Calmette\u2013Gu\u00e9rin Alters Melanoma Microenvironment Favoring Antitumor T Cell Responses and Improving M2 Macrophage Function","volume":"8","author":"Lardone","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3389\/fimmu.2018.00411","article-title":"Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette\u2013Gu\u00e9rin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma","volume":"9","author":"Parakh","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/CJI.0b013e31827457bd","article-title":"Combined intralesional Bacille Calmette-Gu\u00e9rin (BCG) and topical imiquimod for in-transit melanoma","volume":"35","author":"Kidner","year":"2012","journal-title":"J. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/CJI.0000000000000098","article-title":"Treatment of in-transit melanoma with intralesional bacillus Calmette-Gu\u00e9rin (BCG) and topical imiquimod 5% cream: A report of 3 cases","volume":"38","author":"Kibbi","year":"2015","journal-title":"J. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2006.07664.x","article-title":"Phase I\/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma","volume":"156","author":"Green","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/CMR.0b013e328345e95e","article-title":"Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream","volume":"21","author":"Garcia","year":"2011","journal-title":"Melanoma Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaad.2015.06.060","article-title":"100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series","volume":"73","author":"Shi","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jdcr.2016.01.004","article-title":"Treatment of melanoma in-transit metastases with combination intralesional interleukin-2, topical imiquimod, and tretinoin 0.1% cream","volume":"2","author":"Leventhal","year":"2016","journal-title":"JAAD Case Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00262-016-1944-0","article-title":"Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study","volume":"66","author":"Weide","year":"2017","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Rafei-Shamsabadi, D., Lehr, S., von Bubnoff, D., and Meiss, F. (2019). Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. Cancer Immunol. Immunother.","DOI":"10.1007\/s00262-019-02377-x"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"64390","DOI":"10.18632\/oncotarget.10453","article-title":"A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma","volume":"7","author":"Ray","year":"2016","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2326-6066.CIR-13-0206","article-title":"Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses","volume":"2","author":"Weide","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-016-1881-y","article-title":"Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases","volume":"65","author":"Mauldin","year":"2016","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor\u2013Encoding, Second-Generation Oncolytic Herpesvirus in Patients with Unresectable Metastatic Melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/hed.24522","article-title":"Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB\/IIIC\/IV melanoma","volume":"38","author":"Andtbacka","year":"2016","journal-title":"Head Neck"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00262-016-1860-3","article-title":"Systematic review of the use of granulocyte\u2013macrophage colony-stimulating factor in patients with advanced melanoma","volume":"65","author":"Hoeller","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene Laherparepvec Improves Durable Response Rate in Patients with Advanced Melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.cgt.7700019","article-title":"Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma","volume":"6","author":"Nemunaitis","year":"1999","journal-title":"Cancer Gene Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/bjd.17783","article-title":"Talimogene laherparepvec (T-VEC) in advanced melanoma: Complete response in a heart and kidney transplant patient. A case report","volume":"181","author":"Ressler","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/CMR.0000000000000444","article-title":"Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors","volume":"28","author":"Chesney","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination with Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"9568","DOI":"10.1200\/JCO.2016.34.15_suppl.9568","article-title":"Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma","volume":"34","author":"Long","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/jid.2011.247","article-title":"Immunomodulation by imiquimod in patients with high-risk primary melanoma","volume":"132","author":"Narayan","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"ref_54","first-page":"4722","article-title":"Effective innate and adaptive anti-melanoma immunity through localized TLR-7\/8 activation","volume":"193","author":"Singh","year":"2014","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"31792","DOI":"10.18632\/oncotarget.25872","article-title":"A potential novel option for cancer immunotherapy\u2014TLR7 stimulation inhibits malignant melanoma bone invasion","volume":"9","author":"Katagiri","year":"2018","journal-title":"Oncotarget"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1365-2133.2008.08709.x","article-title":"Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1\/Th2 balance in patients with metastatic melanoma","volume":"159","author":"Green","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.jid.2017.12.027","article-title":"T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma","volume":"138","author":"Ogawa","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5929","DOI":"10.1158\/0008-5472.CAN-06-4296","article-title":"Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses","volume":"67","author":"Tuve","year":"2007","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jso.25601","article-title":"Correlates of response and outcomes with talimogene laherperpvec","volume":"120","author":"Zhou","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/CMR.0000000000000399","article-title":"Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma","volume":"28","author":"Chesney","year":"2018","journal-title":"Melanoma Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/00008390-200609001-00012","article-title":"Rose Bengal induces dual modes of cell death in melanoma cells and has clinical activity against melanoma","volume":"16","author":"Mousavi","year":"2006","journal-title":"Melanoma Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/pmj.78.922.449","article-title":"Use of bacille Calmette-Gu\u00e9rin in superficial bladder cancer","volume":"78","author":"Meyer","year":"2002","journal-title":"Postgrad. Med. J."},{"key":"ref_63","first-page":"65","article-title":"Immunotherapy for bladder cancer","volume":"7","author":"Fuge","year":"2015","journal-title":"Res. Rep. Urol."},{"key":"ref_64","first-page":"659","article-title":"Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG","volume":"56","author":"Nathanson","year":"1972","journal-title":"Cancer Chemother. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/1097-0142(197503)35:3<756::AID-CNCR2820350331>3.0.CO;2-Z","article-title":"The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma","volume":"35","author":"Lieberman","year":"1975","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejca.2004.08.010","article-title":"Protection against melanoma by vaccination with Bacille Calmette-Gu\u00e9rin (BCG) and\/or vaccinia: An epidemiology-based hypothesis on the nature of a melanoma risk factor and its immunological control","volume":"41","author":"Krone","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/j.1524-4725.1993.tb00989.x","article-title":"Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma","volume":"19","author":"Tan","year":"1993","journal-title":"J. Dermatol. Surg. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0190-9622(89)70310-8","article-title":"Granulomatous eruption after BCG vaccine immunotherapy for malignant melanoma","volume":"21","author":"Shea","year":"1989","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00000372-198608000-00010","article-title":"Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy","volume":"8","author":"Hutchins","year":"1986","journal-title":"Am. J. Dermatopathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/1097-0142(19820101)49:1<55::AID-CNCR2820490113>3.0.CO;2-F","article-title":"Granulomas in melanoma patients treated with BCG immunotherapy","volume":"49","author":"Hatzitheofilou","year":"1982","journal-title":"Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/1097-0142(197902)43:2<500::AID-CNCR2820430215>3.0.CO;2-U","article-title":"Systemic complications of MER immunotherapy of cancer: Pulmonary granulomatosis and rash","volume":"43","author":"Voith","year":"1979","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archsurg.1978.01370190115025","article-title":"Severe complications of intralesional BCG therapy in an unsensitized patient. Case report and clinical implications","volume":"113","author":"Felix","year":"1978","journal-title":"Arch. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/1097-0142(197803)41:3<820::AID-CNCR2820410306>3.0.CO;2-N","article-title":"Severe thrombocytopenia following intralesional BCG therapy","volume":"41","author":"Norton","year":"1978","journal-title":"Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jso.2930090609","article-title":"Risks of BCG intralesional therapy: An experience with melanoma","volume":"9","author":"Robinson","year":"1977","journal-title":"J. Surg. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/1097-0142(197502)35:2<514::AID-CNCR2820350233>3.0.CO;2-F","article-title":"Immunotherapy of melanoma with BCG: Two fatalities following intralesional injection","volume":"35","author":"McKhann","year":"1975","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/imt.11.46","article-title":"Re-inventing intratumoral immunotherapy for melanoma","volume":"3","author":"Triozzi","year":"2011","journal-title":"Immunotherapy"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/cmi.2016.55","article-title":"Human \u03b3\u03b4T-cell subsets and their involvement in tumor immunity","volume":"14","author":"Wu","year":"2017","journal-title":"Cell. Mol. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0014-5793(03)00483-6","article-title":"Microbial isoprenoid biosynthesis and human gammadelta T cell activation","volume":"544","author":"Eberl","year":"2003","journal-title":"FEBS Lett."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Cordova, A., Toia, F., La Mendola, C., Orlando, V., Meraviglia, S., Rinaldi, G., Todaro, M., Cicero, G., Zichichi, L., and Donni, P.L. (2012). Characterization of Human \u03b3\u03b4 T Lymphocytes Infiltrating Primary Malignant Melanomas. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049878"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20030235","article-title":"Differentiation of Effector\/Memory V\u03b42 T Cells and Migratory Routes in Lymph Nodes or Inflammatory Sites","volume":"198","author":"Dieli","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_81","first-page":"5399","article-title":"Macrophages in skin melanoma-the key element in melanomagenesis","volume":"15","author":"Pieniazek","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_82","first-page":"3461","article-title":"Immunomodulatory Effect of Imiquimod through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas","volume":"37","author":"Furudate","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"29934","DOI":"10.18632\/oncotarget.25711","article-title":"The inhibition of malignant melanoma cell invasion of bone by the TLR7 agonist R848 is dependent upon pro-inflammatory cytokines produced by bone marrow macrophages","volume":"9","author":"Manome","year":"2018","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"684","DOI":"10.18632\/oncotarget.323","article-title":"New perspectives on the role of vitiligo in immune responses to melanoma","volume":"2","author":"Byrne","year":"2011","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1038\/s41598-019-45982-7","article-title":"Retinoic acid and arsenic trioxide induce lasting differentiation and demethylation of target genes in APL cells","volume":"9","author":"Huynh","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e23303","DOI":"10.1002\/dvg.23303","article-title":"Recent insights on the role and regulation of retinoic acid signaling during epicardial development","volume":"57","author":"Wang","year":"2019","journal-title":"Genesis"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Vidovic, D., Huynh, T.T., Konda, P., Dean, C., Cruickshank, B.M., Sultan, M., Coyle, K.M., Gujar, S., and Marcato, P. (2019). ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells. Cell Death Differ., 1\u201316.","DOI":"10.1038\/s41418-019-0362-1"},{"key":"ref_88","first-page":"2100","article-title":"ALDH1A Isozymes Are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets. Stem Cells Dayt","volume":"30","author":"Luo","year":"2012","journal-title":"Ohio"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.immuni.2011.07.002","article-title":"The Role of Retinoic Acid in Tolerance and Immunity","volume":"35","author":"Hall","year":"2011","journal-title":"Immunity"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cellsig.2016.01.012","article-title":"RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1","volume":"28","author":"Szabo","year":"2016","journal-title":"Cell. Signal."},{"key":"ref_91","first-page":"729","article-title":"Retinoic acid increases the anticancer effect of paclitaxel by inducing differentiation of cancer stem cells in melanoma","volume":"73","author":"Wang","year":"2018","journal-title":"Pharmazie"},{"key":"ref_92","first-page":"161","article-title":"Molecular mechanism and cytotoxicity of allicin and all-trans retinoic acid against CD44+ versus CD117+ melanoma cells","volume":"48","author":"Jobani","year":"2018","journal-title":"Phytomed. Int. J. Phytother. Phytopharm."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.gene.2016.07.052","article-title":"Differentiation-inducing and anti-proliferative activities of isoliquiritigenin and all-trans-retinoic acid on B16F0 melanoma cells: Mechanisms profiling by RNA-seq","volume":"592","author":"Chen","year":"2016","journal-title":"Gene"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41467-018-03877-7","article-title":"Inhibition of cancer stem cell like cells by a synthetic retinoid","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/imm.12768","article-title":"Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8+ T-cell immunity","volume":"152","author":"Yin","year":"2017","journal-title":"Immunology"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"11209","DOI":"10.18632\/oncotarget.24359","article-title":"Novel adherent CD11b+ Gr-1+ tumor-infiltrating cells initiate an immunosuppressive tumor microenvironment","volume":"9","author":"Tsubaki","year":"2018","journal-title":"Oncotarget"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1158\/1078-0432.CCR-13-2508","article-title":"Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A\u2013Specific T Cells","volume":"20","author":"Weide","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e12901","DOI":"10.1111\/dth.12901","article-title":"Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma","volume":"32","author":"Langan","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.V99.5.1659","article-title":"Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix","volume":"99","author":"Carnemolla","year":"2002","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/ni.3540","article-title":"An essential role for the IL-2 receptor in Treg cell function","volume":"17","author":"Chinen","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.cgt.7700568","article-title":"A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma","volume":"10","author":"Khorana","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1245\/s10434-018-6803-0","article-title":"Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience","volume":"25","author":"Perez","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"MMT19","DOI":"10.2217\/mmt-2019-0012","article-title":"Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1)","volume":"6","author":"Perez","year":"2019","journal-title":"Melanoma Manag."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jamcollsurg.2018.12.027","article-title":"Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience","volume":"228","author":"Louie","year":"2019","journal-title":"J. Am. Coll. Surg."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CMR.0000000000000501","article-title":"Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma","volume":"29","author":"Seremet","year":"2019","journal-title":"Melanoma Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/CMR.0b013e32831328c7","article-title":"Chemoablation of metastatic melanoma using intralesional Rose Bengal","volume":"18","author":"Thompson","year":"2008","journal-title":"Melanoma Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jso.24921","article-title":"Intralesional PV-10 for the treatment of in-transit melanoma metastases\u2014Results of a prospective, non-randomized, single center study","volume":"117","author":"Read","year":"2018","journal-title":"J. Surg. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jso.24311","article-title":"Intralesional PV-10 for in-transit melanoma-A single-center experience","volume":"114","author":"Lippey","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","article-title":"Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma","volume":"22","author":"Thompson","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"37893","DOI":"10.18632\/oncotarget.9247","article-title":"Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3389\/fimmu.2018.00654","article-title":"Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy","volume":"9","author":"Cruickshank","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jphotobiol.2015.12.001","article-title":"Photosensitized rose Bengal-induced phototoxicity on human melanoma cell line under natural sunlight exposure","volume":"156","author":"Srivastav","year":"2016","journal-title":"J. Photochem. Photobiol. B"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e49020","DOI":"10.7554\/eLife.49020","article-title":"Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction","volume":"8","author":"Wang","year":"2019","journal-title":"eLife"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Khan, S., and Gerber, D.E. (2019). Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Semin. Cancer Biol.","DOI":"10.1016\/j.semcancer.2019.06.012"},{"key":"ref_118","first-page":"653","article-title":"Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared to Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States","volume":"23","author":"Oh","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1001\/jamadermatol.2018.3958","article-title":"Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs. Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma","volume":"155","author":"Almutairi","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_120","unstructured":"(2019, December 18). Pan-Canadian Oncology Drug Review. pan-Canadian Oncology Drug Review Final Economic Guidance Report: Aldesleukin (Proleukin) for In-Transit. Melanoma. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_adesleukin_proleukin_fn_egr.pdf."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1321\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:31:27Z","timestamp":1760175087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,22]]},"references-count":120,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051321"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051321","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,22]]}}}